PMID- 32071906
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220412
IS  - 2235-1795 (Print)
IS  - 1664-5553 (Electronic)
IS  - 1664-5553 (Linking)
VI  - 9
IP  - 1
DP  - 2020 Jan
TI  - Surgical Treatment of Hepatocholangiocarcinoma: A Systematic Review.
PG  - 15-27
LID - 10.1159/000503719 [doi]
AB  - BACKGROUND: Hepatocholangiocarcinoma (HCC-CC) is a rare liver malignancy that 
      contains features of both hepatocellular carcinoma (HCC) and mass-forming 
      cholangiocarcinoma (MFCCC). Three classification systems for HCC-CC are described 
      in literature and the majority of these tumors appear to be of the transitional 
      type. The aim of this study is to evaluate the characteristics of transitional 
      HCC-CC and to compare long-term oncological outcomes with HCC and MFCCC in 
      surgically treated patients. SUMMARY: A systematic literature search was 
      conducted to identify relevant studies analyzing demographic and clinical 
      characteristics of patients with transitional HCC-CC and evaluating treatments 
      and outcomes associated with this neoplasm. Only comparative, retrospective 
      analyses were included. A total of 14 studies, involving 13,613 patients with 
      primary liver malignancy, were analyzed. All patients underwent surgery, either 
      liver resection or transplantation. Four hundred and thirty-seven patients were 
      affected by transitional HCC-CC (3.2%). For further analysis, patients with 
      transitional HCC-CC were divided into 2 groups, the resection group and the 
      transplantation group. Disease-free survival (DFS) and overall survival (OS) of 
      these patients were analyzed and compared to long-term oncological outcomes of 
      patients with HCC and/or MFCCC, who underwent the same treatment. In the 
      resection group, DFS rate at 5-year was 15, 31.6, and 20.3% for patients with 
      transitional HCC-CC, HCC, and MFCCC, respectively; OS rate at 5-year was 32.7, 
      47.5, and 30.3% for patients with transitional HCC-CC, HCC, and MFCCC, 
      respectively. In the transplantation group, DFS rate at 5-year was 40.9 and 87.4% 
      for patients with transitional HCC-CC and HCC, respectively; OS rate at 5-year 
      was 49.4 and 80.3% for patients with transitional HCC-CC and HCC, respectively. 
      KEY MESSAGES: Transitional HCC-CC patients have significantly worse DFS and OS 
      rates compared to HCC patients in both the resection group and the 
      transplantation group. However, in the resection group, both DFS and OS rates of 
      transitional HCC-CC patients are not statistically different from those of MFCCC 
      patients.
CI  - Copyright (c) 2019 by S. Karger AG, Basel.
FAU - Gentile, Damiano
AU  - Gentile D
AD  - aDepartment of Hepatobiliary and General Surgery, Humanitas University, Humanitas 
      Clinical and Research Center, IRCCS, Rozzano, Milan, Italy.
FAU - Donadon, Matteo
AU  - Donadon M
AD  - aDepartment of Hepatobiliary and General Surgery, Humanitas University, Humanitas 
      Clinical and Research Center, IRCCS, Rozzano, Milan, Italy.
FAU - Lleo, Ana
AU  - Lleo A
AD  - bDepartment of Internal Medicine and Hepatology, Humanitas University, Humanitas 
      Clinical and Research Center, IRCCS, Rozzano, Milan, Italy.
FAU - Aghemo, Alessio
AU  - Aghemo A
AD  - bDepartment of Internal Medicine and Hepatology, Humanitas University, Humanitas 
      Clinical and Research Center, IRCCS, Rozzano, Milan, Italy.
FAU - Roncalli, Massimo
AU  - Roncalli M
AD  - cDepartment of Pathology, Humanitas University, Humanitas Clinical and Research 
      Center, IRCCS, Rozzano, Milan, Italy.
FAU - di Tommaso, Luca
AU  - di Tommaso L
AD  - cDepartment of Pathology, Humanitas University, Humanitas Clinical and Research 
      Center, IRCCS, Rozzano, Milan, Italy.
FAU - Torzilli, Guido
AU  - Torzilli G
AD  - aDepartment of Hepatobiliary and General Surgery, Humanitas University, Humanitas 
      Clinical and Research Center, IRCCS, Rozzano, Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20191101
PL  - Switzerland
TA  - Liver Cancer
JT  - Liver cancer
JID - 101597993
PMC - PMC7024854
OTO - NOTNLM
OT  - Cholangiocarcinoma
OT  - Hepatocellular carcinoma
OT  - Hepatocholangiocarcinoma
OT  - Liver neoplasms
COIS- The authors have no conflicts of interest to declare.
EDAT- 2020/02/20 06:00
MHDA- 2020/02/20 06:01
PMCR- 2019/11/01
CRDT- 2020/02/20 06:00
PHST- 2019/05/20 00:00 [received]
PHST- 2019/09/13 00:00 [accepted]
PHST- 2020/02/20 06:00 [entrez]
PHST- 2020/02/20 06:00 [pubmed]
PHST- 2020/02/20 06:01 [medline]
PHST- 2019/11/01 00:00 [pmc-release]
AID - lic-0009-0015 [pii]
AID - 10.1159/000503719 [doi]
PST - ppublish
SO  - Liver Cancer. 2020 Jan;9(1):15-27. doi: 10.1159/000503719. Epub 2019 Nov 1.